SPY305.55+1.23 0.40%
DIA255.27+0.98 0.39%
IXIC9,552.05+62.18 0.66%

Exelixis Reports Results From COSMIC-021 Trial Of Cabozantinib In Combo With Atezolizumab In Multiple Advanced Solid Tumor Types

Benzinga · 05/13/2020 21:08